These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9622056)

  • 41. Antigen presenting cells.
    Hamilos DL
    Immunol Res; 1989; 8(2):98-117. PubMed ID: 2659691
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of oncogenes in the regulation of MHC antigen expression.
    Maudsley DJ
    Biochem Soc Trans; 1991 Apr; 19(2):291-6. PubMed ID: 1716227
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The regulation of expression of histocompatibility antigens on the cell surface; molecular genetic basis.
    Petrányi GG
    Folia Biol (Praha); 1995; 41(3-4):163-77. PubMed ID: 7589712
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current developments in cancer vaccines and cellular immunotherapy.
    Ribas A; Butterfield LH; Glaspy JA; Economou JS
    J Clin Oncol; 2003 Jun; 21(12):2415-32. PubMed ID: 12805342
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Induction of antigen-presenting capacity in tumor cells upon infection with non-replicating recombinant vaccinia virus encoding murine MHC class II and costimulatory molecules.
    Marti WR; Oertli D; Meko JB; Norton JA; Tsung K
    J Immunol Methods; 1997 Jan; 200(1-2):191-8. PubMed ID: 9005958
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mechanisms of antigen presentation.
    Jensen PE
    Clin Chem Lab Med; 1999 Mar; 37(3):179-86. PubMed ID: 10353458
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Escape from host-antitumor immunity.
    Pawelec G; Zeuthen J; Kiessling R
    Crit Rev Oncog; 1997; 8(2-3):111-41. PubMed ID: 9570292
    [TBL] [Abstract][Full Text] [Related]  

  • 48. SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4
    Lacher MD; Bauer G; Fury B; Graeve S; Fledderman EL; Petrie TD; Coleal-Bergum DP; Hackett T; Perotti NH; Kong YY; Kwok WW; Wagner JP; Wiseman CL; Williams WV
    Front Immunol; 2018; 9():776. PubMed ID: 29867922
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interleukin 1 alpha but not transforming growth factor beta inhibits tumor antigen presentation by epidermal antigen-presenting cells.
    Grabbe S; Bruvers S; Granstein RD
    J Invest Dermatol; 1994 Jan; 102(1):67-73. PubMed ID: 8288913
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Modulation by canine interferon-gamma of major histocompatibility complex and tumor-associated antigen expression in canine mammary tumor and melanoma cell lines.
    Whitley EM; Bird AC; Zucker KE; Wolfe LG
    Anticancer Res; 1995; 15(3):923-9. PubMed ID: 7645983
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antigen-Presenting Cell Characteristics of Human γδ T Lymphocytes in Chronic Myeloid Leukemia.
    Sawaisorn P; Tangchaikeeree T; Chan-On W; Leepiyasakulchai C; Udomsangpetch R; Hongeng S; Jangpatarapongsa K
    Immunol Invest; 2019 Jan; 48(1):11-26. PubMed ID: 30321079
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Molecular bases of cancer immunology].
    Barrera-Rodríguez R; Peralta-Zaragoza O; Madrid-Marina V
    Salud Publica Mex; 1995; 37(4):344-53. PubMed ID: 7502157
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influence of major histocompatibility complex class I, class II and TLA genes on tumor rejection.
    Ostrand-Rosenberg S; Garcia EP; Roby CA; Clements VK
    Semin Cancer Biol; 1991 Oct; 2(5):311-9. PubMed ID: 1773047
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The cell mediated immune response].
    Haurum JS
    Ugeskr Laeger; 1995 Jul; 157(27):3887-93. PubMed ID: 7645062
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
    Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
    Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen.
    Wang RF; Parkhurst MR; Kawakami Y; Robbins PF; Rosenberg SA
    J Exp Med; 1996 Mar; 183(3):1131-40. PubMed ID: 8642255
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quantitative aspects of T-cell recognition: from within the antigen-presenting cell to within the T cell.
    Bongrand P; Malissen B
    Bioessays; 1998 May; 20(5):412-22. PubMed ID: 9670814
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells.
    Lizée G; Gonzales MI; Topalian SL
    Hum Gene Ther; 2004 Apr; 15(4):393-404. PubMed ID: 15053864
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Exosomes: a new delivery system for tumor antigens in cancer immunotherapy.
    Cho JA; Yeo DJ; Son HY; Kim HW; Jung DS; Ko JK; Koh JS; Kim YN; Kim CW
    Int J Cancer; 2005 Apr; 114(4):613-22. PubMed ID: 15609328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.